bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

TP53 mutations in formalin fixed paraffin embedded cell lines stratified by immunohistochemistry (IHC) result. Bolded results indicate discordant samples.
Supplemental Material from A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Authors: Prat Aleix , Lluch Ana , Turnbull Arran K. , Dunbier Anita K. , Calvo Lourdes , Albanell Joan , de la Haba-Rodríguez Juan , Arcusa Angels , Chacón José Ignacio , Sánchez-Rovira Pedro , Plazaola Arrate , Muñoz Montserrat , Paré Laia , Parker Joel S. , Ribelles Nuria , Jimenez Begoña , Bin Aiderus Abdul Aziz , Caballero Rosalía , Adamo Barbara , Dowsett Mitch , Carrasco Eva , Martín Miguel , Dixon J. Michael , Perou Charles M. , Alba Emilio
Published: April 2023

All raw gene expression and clinical data
Supplementary Table S3 from Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Authors: Lohavanichbutr Pawadee , Sakoda Lori C. , Amos Christopher I. , Arnold Susanne M. , Christiani David C. , Davies Michael P.A. , Field John K. , Haura Eric B. , Hung Rayjean J. , Kohno Takashi , Landi Maria Teresa , Liu Geoffrey , Liu Yi , Marcus Michael W. , O'Kane Grainne M. , Schabath Matthew B. , Shiraishi Kouya , Slone Stacey A. , Tardón Adonina , Yang Ping , Yoshida Kazushi , Zhang Ruyang , Zong Xuchen , Goodman Gary E. , Weiss Noel S. , Chen Chu
Published: April 2023

Distribution of rs942190 and rs2401863 by race
Spearman coefficients of correlation from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
Authors: Terry Kathryn L. , Schock Helena , Fortner Renée T. , Hüsing Anika , Fichorova Raina N. , Yamamoto Hidemi S. , Vitonis Allison F. , Johnson Theron , Overvad Kim , Tjønneland Anne , Boutron-Ruault Marie-Christine , Mesrine Sylvie , Severi Gianluca , Dossus Laure , Rinaldi Sabina , Boeing Heiner , Benetou Vassiliki , Lagiou Pagona , Trichopoulou Antonia , Krogh Vittorio , Kuhn Elisabetta , Panico Salvatore , Bueno-de-Mesquita H. Bas , Onland-Moret N. Charlotte , Peeters Petra H. , Gram Inger Torhild , Weiderpass Elisabete , Duell Eric J. , Sanchez Maria-Jose , Ardanaz Eva , Etxezarreta Nerea , Navarro Carmen , Idahl Annika , Lundin Eva , Jirström Karin , Manjer Jonas , Wareham Nicholas J. , Khaw Kay-Tee , Byrne Karl Smith , Travis Ruth C. , Gunter Marc J. , Merritt Melissa A. , Riboli Elio , Cramer Daniel W. , Kaaks Rudolf
Published: April 2023

Spearman coefficients of correlation between detection markers
Supplementary Table S1 from Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Authors: Lohavanichbutr Pawadee , Sakoda Lori C. , Amos Christopher I. , Arnold Susanne M. , Christiani David C. , Davies Michael P.A. , Field John K. , Haura Eric B. , Hung Rayjean J. , Kohno Takashi , Landi Maria Teresa , Liu Geoffrey , Liu Yi , Marcus Michael W. , O'Kane Grainne M. , Schabath Matthew B. , Shiraishi Kouya , Slone Stacey A. , Tardón Adonina , Yang Ping , Yoshida Kazushi , Zhang Ruyang , Zong Xuchen , Goodman Gary E. , Weiss Noel S. , Chen Chu
Published: April 2023

List of tag SNPs for the TDP1 gene region
ROC curves and C-statistics by tumor stage from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
Authors: Terry Kathryn L. , Schock Helena , Fortner Renée T. , Hüsing Anika , Fichorova Raina N. , Yamamoto Hidemi S. , Vitonis Allison F. , Johnson Theron , Overvad Kim , Tjønneland Anne , Boutron-Ruault Marie-Christine , Mesrine Sylvie , Severi Gianluca , Dossus Laure , Rinaldi Sabina , Boeing Heiner , Benetou Vassiliki , Lagiou Pagona , Trichopoulou Antonia , Krogh Vittorio , Kuhn Elisabetta , Panico Salvatore , Bueno-de-Mesquita H. Bas , Onland-Moret N. Charlotte , Peeters Petra H. , Gram Inger Torhild , Weiderpass Elisabete , Duell Eric J. , Sanchez Maria-Jose , Ardanaz Eva , Etxezarreta Nerea , Navarro Carmen , Idahl Annika , Lundin Eva , Jirström Karin , Manjer Jonas , Wareham Nicholas J. , Khaw Kay-Tee , Byrne Karl Smith , Travis Ruth C. , Gunter Marc J. , Merritt Melissa A. , Riboli Elio , Cramer Daniel W. , Kaaks Rudolf
Published: April 2023

ROC curves and C-statistics by tumor stage for diagnosis {less than or equal to}6 months, {less than or equal to}12 months, 1-2 years and 2-3 years after blood collection
GlycoCirrhoTest and related glycomics-based biomarkers for liver disease from A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis
Authors: Verhelst Xavier , Vanderschaeghe Dieter , Castéra Laurent , Raes Tom , Geerts Anja , Francoz Claire , Colman Roos , Durand François , Callewaert Nico , Van Vlierberghe Hans
Published: April 2023

This file gives additional information regarding the GlycoCirrhoTest and other glycomics-based test based on the same technology (DSA-FACE) for glycomic analysis.
Case characteristics from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
Authors: Terry Kathryn L. , Schock Helena , Fortner Renée T. , Hüsing Anika , Fichorova Raina N. , Yamamoto Hidemi S. , Vitonis Allison F. , Johnson Theron , Overvad Kim , Tjønneland Anne , Boutron-Ruault Marie-Christine , Mesrine Sylvie , Severi Gianluca , Dossus Laure , Rinaldi Sabina , Boeing Heiner , Benetou Vassiliki , Lagiou Pagona , Trichopoulou Antonia , Krogh Vittorio , Kuhn Elisabetta , Panico Salvatore , Bueno-de-Mesquita H. Bas , Onland-Moret N. Charlotte , Peeters Petra H. , Gram Inger Torhild , Weiderpass Elisabete , Duell Eric J. , Sanchez Maria-Jose , Ardanaz Eva , Etxezarreta Nerea , Navarro Carmen , Idahl Annika , Lundin Eva , Jirström Karin , Manjer Jonas , Wareham Nicholas J. , Khaw Kay-Tee , Byrne Karl Smith , Travis Ruth C. , Gunter Marc J. , Merritt Melissa A. , Riboli Elio , Cramer Daniel W. , Kaaks Rudolf
Published: April 2023

Case characteristics (median (min-max) or n (%)) by histologic subtypes in the EPIC cohort
Supplementary Figures from The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer
Authors: Rebello Richard J. , Kusnadi Eric , Cameron Donald P. , Pearson Helen B. , Lesmana Analia , Devlin Jennifer R. , Drygin Denis , Clark Ashlee K. , Porter Laura , Pedersen John , Sandhu Shahneen , Risbridger Gail P. , Pearson Richard B. , Hannan Ross D. , Furic Luc
Published: April 2023

Fig S1: Generation and characterisation of an androgen-dependent Hi-MYC epithelial line from 5-month Hi-MYC lateral prostate adenocarcinoma. Fig S2: CX-6258 does not inhibit Ribosomal RNA transcription. Fig S3: CX-6258 does not induce p53, but does induce low level p21 expression Fig S4: CX-5461 co-operates with Everolimus (RAD001) in vitro, but this does not suppress Hi-MYC tumorigenesis Fig S5: 5 month old Hi-MYC mouse prostate and body weight Fig S6: Influence of the androgen receptor on growth inhibition sensitivity
Supplementary Table 5 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Authors: Xu Jian-Ming , Wang Yan , Wang You-Liang , Liu Tao , Ni Ming , Li Man-Sheng , Lin Li , Ge Fei-Jiao , Gong Chun , Gu Jun-Yan , Jia Ru , Wang He-Fei , Chen Yu-Ling , Liu Rong-Rui , Zhao Chuan-Hua , Tan Zhao-Li , Jin Yang , Zhu Yun-Ping , Ogino Shuji , Qian Zhi-Rong
Published: April 2023

Dynamics of mutations related to acquired resistance in validation cohort
Supplementary Table 1 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

Histopathologic characteristics of 42 pituitary adenomas
Supplementary Table 4 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Authors: Xu Jian-Ming , Wang Yan , Wang You-Liang , Liu Tao , Ni Ming , Li Man-Sheng , Lin Li , Ge Fei-Jiao , Gong Chun , Gu Jun-Yan , Jia Ru , Wang He-Fei , Chen Yu-Ling , Liu Rong-Rui , Zhao Chuan-Hua , Tan Zhao-Li , Jin Yang , Zhu Yun-Ping , Ogino Shuji , Qian Zhi-Rong
Published: April 2023

Clinical information of validation cohort
Supplementary Table 3 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Authors: Xu Jian-Ming , Wang Yan , Wang You-Liang , Liu Tao , Ni Ming , Li Man-Sheng , Lin Li , Ge Fei-Jiao , Gong Chun , Gu Jun-Yan , Jia Ru , Wang He-Fei , Chen Yu-Ling , Liu Rong-Rui , Zhao Chuan-Hua , Tan Zhao-Li , Jin Yang , Zhu Yun-Ping , Ogino Shuji , Qian Zhi-Rong
Published: April 2023

Dynamics of mutations related to acquired resistance in plasma samples of development cohort
Supplementary Table 2 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Authors: Xu Jian-Ming , Wang Yan , Wang You-Liang , Liu Tao , Ni Ming , Li Man-Sheng , Lin Li , Ge Fei-Jiao , Gong Chun , Gu Jun-Yan , Jia Ru , Wang He-Fei , Chen Yu-Ling , Liu Rong-Rui , Zhao Chuan-Hua , Tan Zhao-Li , Jin Yang , Zhu Yun-Ping , Ogino Shuji , Qian Zhi-Rong
Published: April 2023

Potential effects on protein function of candidate mutations identified in cfDNA, as predicted using PolyPhen-2 and SIFT
Table S2 from Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
Authors: Wang Zheng , Ren Zhenggang , Chen Yi , Hu Jie , Yang Guohuan , Yu Lei , Yang Xinrong , Huang Ao , Zhang Xin , Zhou Shaolai , Sun Huichuan , Wang Yanhong , Ge Ningling , Xu Xiaoyu , Tang Zhaoyou , Lau Wanyee , Fan Jia , Wang Jiping , Zhou Jian
Published: April 2023

Table S1 shows adverse events for the adjuvant TACE group at the censor of follow-up
Supplementary Figure S5 from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

Prognostic impact of ABCF1 alone or in combination with IGF2BP3
Table S1 from Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
Authors: Wang Zheng , Ren Zhenggang , Chen Yi , Hu Jie , Yang Guohuan , Yu Lei , Yang Xinrong , Huang Ao , Zhang Xin , Zhou Shaolai , Sun Huichuan , Wang Yanhong , Ge Ningling , Xu Xiaoyu , Tang Zhaoyou , Lau Wanyee , Fan Jia , Wang Jiping , Zhou Jian
Published: April 2023

Table S1 shows univariable analysis of influencing factors for RFS and OS
Supplementary Figure S3 from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

Characterization of IGF2BP3-silenced ES cellular models
Supplemental Table S3: Actionable gene list for the Precision Oncology Decision Support (PODS) team at MD Anderson Cancer Center (as of November 1, 2017) from Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Authors: Kurnit Katherine C. , Dumbrava Ecaterina E. Ileana , Litzenburger Beate , Khotskaya Yekaterina B. , Johnson Amber M. , Yap Timothy A. , Rodon Jordi , Zeng Jia , Shufean Md Abu , Bailey Ann M. , Sánchez Nora S. , Holla Vijaykumar , Mendelsohn John , Shaw Kenna Mills , Bernstam Elmer V. , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Actionable gene list for the Precision Oncology Decision Support (PODS) team at MD Anderson Cancer Center (as of November 1, 2017)
Supplementary Figure S2 from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

IGF2BP3 expression in ES cells after EWS-FLI1 silencing
Supplemental Table S2: Prominent commercial vendors providing decision support services (as of November 1, 2017) from Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Authors: Kurnit Katherine C. , Dumbrava Ecaterina E. Ileana , Litzenburger Beate , Khotskaya Yekaterina B. , Johnson Amber M. , Yap Timothy A. , Rodon Jordi , Zeng Jia , Shufean Md Abu , Bailey Ann M. , Sánchez Nora S. , Holla Vijaykumar , Mendelsohn John , Shaw Kenna Mills , Bernstam Elmer V. , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Prominent commercial vendors providing decision support services (as of November 1, 2017)
Figure S3 from CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
Authors: Edwards Jarem , Wilmott James S. , Madore Jason , Gide Tuba Nur , Quek Camelia , Tasker Annie , Ferguson Angela , Chen Jinbiao , Hewavisenti Rehana , Hersey Peter , Gebhardt Thomas , Weninger Wolfgang , Britton Warwick J. , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Long Georgina V. , Scolyer Richard A. , Palendira Umaimainthan
Published: April 2023

Supplementary data on gating strategy used in the study
Figure S2 from CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
Authors: Edwards Jarem , Wilmott James S. , Madore Jason , Gide Tuba Nur , Quek Camelia , Tasker Annie , Ferguson Angela , Chen Jinbiao , Hewavisenti Rehana , Hersey Peter , Gebhardt Thomas , Weninger Wolfgang , Britton Warwick J. , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Long Georgina V. , Scolyer Richard A. , Palendira Umaimainthan
Published: April 2023

Supplementary data on flow cytometry analysis
Supplemental Table 3 from The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Authors: Salomon Matthew P. , Wang Xiaowen , Marzese Diego M. , Hsu Sandy C. , Nelson Nellie , Zhang Xin , Matsuba Chikako , Takasumi Yuki , Ballesteros-Merino Carmen , Fox Bernard A. , Barkhoudarian Garni , Kelly Daniel F. , Hoon Dave S.B.
Published: April 2023

GH-secreting PAs starburst plot gene details. The top 50 most significantly differentially expressed genes contained within Figure 5 for GH-secreting PAs as compared to endocrine-inactive PAs. The table has five columns; 1) gene symbol, 2) Entrez ID number, 3) the log fold change value from the RNA-seq differential expression analysis comparing GH-secreting PAs to endocrine-inactive PAs, 4) the change in methylation beta values between GH-secreting PAs and endocrine-inactive PAs, and 5) the genomic feature for the methylation data.
Supplemental Table 1 from The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Authors: Salomon Matthew P. , Wang Xiaowen , Marzese Diego M. , Hsu Sandy C. , Nelson Nellie , Zhang Xin , Matsuba Chikako , Takasumi Yuki , Ballesteros-Merino Carmen , Fox Bernard A. , Barkhoudarian Garni , Kelly Daniel F. , Hoon Dave S.B.
Published: April 2023

Table of clinical parameters for each patient sample.
Figure S1-S3 from Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Authors: Liu Shengwu , Li Shuai , Hai Josephine , Wang Xiaoen , Chen Ting , Quinn Max M. , Gao Peng , Zhang Yanxi , Ji Hongbin , Cross Darren A.E. , Wong Kwok-Kin
Published: April 2023

Fig S1. Copy number of human HER2 in HW mice (A) Blood sample was collected from HW mouse and used for fluorescence in situ hybridization (FISH) with hHER2 gene labeled in red/orange and internal 2-copy control D15Mit224 labeled in green. (B) Summary of hHER2 copy number using both FISH and real-time qPCR. gDNA was extracted from HW mouse ear tissues and real-time qPCR based copy number assay was performed to identify the copy number of human HER2. The 2-copy mouse TERT gene was used as internal control. Fig. S2 Tumor growth curve and the overall survival curve of HW mice with doxy induction (A) Tumor growth curve for 16 weeks from MRI data. (B) Overall survival curve of HW mice after doxycycline food induction. Fig. S3 Efficacy of erlotinib and osimertinib against EGFR-del19 lung tumors Del19 mice were treated with either erlotinib or osimertinib for 4 weeks and tumor volume change is shown as waterfall plot. Each column shows one mouse.
Supplemental Figure 1 from The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Authors: Salomon Matthew P. , Wang Xiaowen , Marzese Diego M. , Hsu Sandy C. , Nelson Nellie , Zhang Xin , Matsuba Chikako , Takasumi Yuki , Ballesteros-Merino Carmen , Fox Bernard A. , Barkhoudarian Garni , Kelly Daniel F. , Hoon Dave S.B.
Published: April 2023

PCA analysis of genome-wide methylation profiles. PCA analysis using all probes in the methylation data set. Points are colored by the percent of the genome altered by SCNAs. The three PA subtypes are indicated by the shape of the points, with GH-secreting PAs represented by dots, ACTH-secreting PAs represented by triangles, and endocrine-inactive PAs represented by squares. Ellipses indicate 95% confidence intervals. Overall, PAs cluster by PA subtype and not by the percent of the genome disrupted by SCNAs.
Table S3 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

Cox proportional hazard analyses show that LDHA protein is independently associated with OS but not EFS in NB.
Table S2 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

Cox proportional hazard analyses show that LDHA mRNA is independently associated with OS and EFS in NB.
Table S1 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

Primers used for PCR-analysis
Supplemental Figure Legend from Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Authors: Tang Chad , Sherman Steven I. , Price Mellanie , Weng Jun , Davis Suzanne E. , Hong David S. , Yao James C. , Buzdar Aman , Wilding George , Lee J. Jack
Published: April 2023

Figure legend for supplemental figures
Supplemental Figure 2 from Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Authors: Tang Chad , Sherman Steven I. , Price Mellanie , Weng Jun , Davis Suzanne E. , Hong David S. , Yao James C. , Buzdar Aman , Wilding George , Lee J. Jack
Published: April 2023

Slow accruing national cooperative group trials with respect to submission year
Figure S3 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

LDHC mRNA expression is very low in NB cell lines and patients
Table S1 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

CLL features
Figure S4 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

phosphor AKT
Supplementary Figure 11 from Recurrent TRIO Fusion in Nontranslocation–Related Sarcomas
Authors: Delespaul Lucile , Lesluyes Tom , Pérot Gaëlle , Brulard Céline , Lartigue Lydia , Baud Jessica , Lagarde Pauline , Le Guellec Sophie , Neuville Agnès , Terrier Philippe , Vince-Ranchère Dominique , Schmidt Susanne , Debant Anne , Coindre Jean-Michel , Chibon Frédéric
Published: April 2023

Schematics of predicted TRIO fusions proteins.
Suppl. Table S2 & S3 from HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue
Authors: Zheng Guopei , Zhang Zhijie , Liu Hao , Xiong Yan , Luo Liyun , Jia Xiaoting , Peng Cong , Zhang Qiong , Li Nan , Gu Yixue , Lu Minying , Song Ying , Pan Hao , Liu Jinbao , Liu Wanqing , He Zhimin
Published: April 2023

Table S2. Correlation of HSP27 level with clinicopathological parameters in cohort1; Table S3. Correlation of HSP27 level with clinicopathological parameters in cohort2.
Suppl. Table S1 from HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue
Authors: Zheng Guopei , Zhang Zhijie , Liu Hao , Xiong Yan , Luo Liyun , Jia Xiaoting , Peng Cong , Zhang Qiong , Li Nan , Gu Yixue , Lu Minying , Song Ying , Pan Hao , Liu Jinbao , Liu Wanqing , He Zhimin
Published: April 2023

Table S1. Identified differential protein spots between SCC-15 and SCC-15/PYM cell lines.
Suppl. Figures 1-6 from HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue
Authors: Zheng Guopei , Zhang Zhijie , Liu Hao , Xiong Yan , Luo Liyun , Jia Xiaoting , Peng Cong , Zhang Qiong , Li Nan , Gu Yixue , Lu Minying , Song Ying , Pan Hao , Liu Jinbao , Liu Wanqing , He Zhimin
Published: April 2023

Suppl. Figures 1-6
Suppl. Figures S2-4 from Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
Authors: Odate Seiichi , Veschi Veronica , Yan Shuang , Lam Norris , Woessner Richard , Thiele Carol J.
Published: April 2023

These are the original Supplementary Figures S2-S4.
Suppl. Data from HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue
Authors: Zheng Guopei , Zhang Zhijie , Liu Hao , Xiong Yan , Luo Liyun , Jia Xiaoting , Peng Cong , Zhang Qiong , Li Nan , Gu Yixue , Lu Minying , Song Ying , Pan Hao , Liu Jinbao , Liu Wanqing , He Zhimin
Published: April 2023

Suppl. Data
Table 1 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
Authors: McCoach Caroline E. , Blakely Collin M. , Banks Kimberly C. , Levy Benjamin , Chue Ben M. , Raymond Victoria M. , Le Anh T. , Lee Christine E. , Diaz Joseph , Waqar Saiama N. , Purcell William T. , Aisner Dara L. , Davies Kurtis D. , Lanman Richard B. , Shaw Alice T. , Doebele Robert C.
Published: April 2023

Cohort 2 breakpoint table
Table S7 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

Summary of hits from ponatinib analyses and target expression.
Table S5-6 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

Supplemental Table 5. SCCOHT-1 ABPP data; Supplemental Table 6. BIN67 ABPP data.
Table S4 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

MIB-MS data.
Table S2 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

List of high-throughput drug screen hits.
Table S1 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Authors: Lang Jessica D. , Hendricks William P.D. , Orlando Krystal A. , Yin Hongwei , Kiefer Jeffrey , Ramos Pilar , Sharma Ritin , Pirrotte Patrick , Raupach Elizabeth A. , Sereduk Chris , Tang Nanyun , Liang Winnie S. , Washington Megan , Facista Salvatore J. , Zismann Victoria L. , Cousins Emily M. , Major Michael B. , Wang Yemin , Karnezis Anthony N. , Sekulic Aleksandar , Hass Ralf , Vanderhyden Barbara C. , Nair Praveen , Weissman Bernard E. , Huntsman David G. , Trent Jeffrey M.
Published: April 2023

List of validated siRNA screen hits.
Supplementary Figures and Tables from Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing
Authors: Roberts Brian S. , Hardigan Andrew A. , Moore Dianna E. , Ramaker Ryne C. , Jones Angela L. , Fitz-Gerald Meredith B. , Cooper Gregory M. , Wilcox C. Mel , Kimberly Robert P. , Myers Richard M.
Published: April 2023

Supplemental figures and tables reference in the manuscript
Table S2 from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Authors: Hamilton Erika P. , Patel Manish R. , Armstrong Anne C. , Baird Richard D. , Jhaveri Komal , Hoch Matthias , Klinowska Teresa , Lindemann Justin P.O. , Morgan Shethah R. , Schiavon Gaia , Weir Hazel M. , Im Seock-Ah
Published: April 2023

PK parameters for M5 following a single dose (Day 1) and multiple doses (Day 15)
Table S2 from Establishing a Preclinical Multidisciplinary Board for Brain Tumors
Authors: Nimmervoll Birgit V. , Boulos Nidal , Bianski Brandon , Dapper Jason , DeCuypere Michael , Shelat Anang , Terranova Sabrina , Terhune Hope E. , Gajjar Amar , Patel Yogesh T. , Freeman Burgess B. , Onar-Thomas Arzu , Stewart Clinton F. , Roussel Martine F. , Guy R. Kipling , Merchant Thomas E. , Calabrese Christopher , Wright Karen D. , Gilbertson Richard J.
Published: April 2023

information on drugs used in preclinical studies
Figure S2C and S2D: Geometric mean plasma concentration-time profiles of AZD9496 metabolites M3 (A and B) and M5 (C and D) following a single dose and multiple doses of AZD9496 (n = 3-5 subjects) from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Authors: Hamilton Erika P. , Patel Manish R. , Armstrong Anne C. , Baird Richard D. , Jhaveri Komal , Hoch Matthias , Klinowska Teresa , Lindemann Justin P.O. , Morgan Shethah R. , Schiavon Gaia , Weir Hazel M. , Im Seock-Ah
Published: April 2023

AZD9496 metabolite, M3 (Panel A) and M5 (Panel C), geometric mean plasma concentration following a single dose of AZD9496 on Day 1 (semi-log scale). AZD9496 metabolite, M3 (Panel B) and M5 (Panel D), geometric mean plasma concentration following multiple doses of AZD9496 on Day 15 (semi-log scale). On Day 15 at all doses except 20 mg, the 24 h time point is the 12 h trough concentration following the evening dose of AZD9496 and therefore not shown. aPooled data from dose escalation and expansion groups. BID=twice daily; QD=once daily; EXP=expansion cohort.
Methods file from Establishing a Preclinical Multidisciplinary Board for Brain Tumors
Authors: Nimmervoll Birgit V. , Boulos Nidal , Bianski Brandon , Dapper Jason , DeCuypere Michael , Shelat Anang , Terranova Sabrina , Terhune Hope E. , Gajjar Amar , Patel Yogesh T. , Freeman Burgess B. , Onar-Thomas Arzu , Stewart Clinton F. , Roussel Martine F. , Guy R. Kipling , Merchant Thomas E. , Calabrese Christopher , Wright Karen D. , Gilbertson Richard J.
Published: April 2023

Supplementary Methods
Figure S1: Doses given and DLTs experienced in the dose escalation and dose expansion cohorts from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Authors: Hamilton Erika P. , Patel Manish R. , Armstrong Anne C. , Baird Richard D. , Jhaveri Komal , Hoch Matthias , Klinowska Teresa , Lindemann Justin P.O. , Morgan Shethah R. , Schiavon Gaia , Weir Hazel M. , Im Seock-Ah
Published: April 2023

A total of 45 patients were recruited and four to six patients were allocated to cohorts to receive escalating doses of AZD9496. In the BID cohorts, patients received QD dosing on Day 1 and BID dosing thereafter. Six patients entered the expansion cohort, receiving AZD9496 250 mg BID. BID=twice daily, DLT=dose-limiting toxicity; n=number of patients included; LFT=liver function tests; QD=once daily.
Table S6. Cohort copy number variations. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

This table presents all CNVs identified among our cohort using the ONCOCNV software. Duplication was considered when copy number was superior to 2 and deletion was considered when copy number was inferior to 2. False discovery rate (FDR) cutoff was set at 0.01.
Table S1. Clinical and immunohistochemical data according to MYD88 mutation status. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

All relevant clinical data is included. Immunohistochemical results for BCL2, CD10, BCL6, MUM1, FOXP1, IgM and MYC are transcribed: 0 indicates negativity and 1 indicates positivity. For BCL2 and MYC, positivity is according to a threshold of 50% or 40% respectively.
Supplementary Data from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Authors: Dubois Sydney , Viailly Pierre-Julien , Bohers Elodie , Bertrand Philippe , Ruminy Philippe , Marchand Vinciane , Maingonnat Catherine , Mareschal Sylvain , Picquenot Jean-Michel , Penther Dominique , Jais Jean-Philippe , Tesson Bruno , Peyrouze Pauline , Figeac Martin , Desmots Fabienne , Fest Thierry , Haioun Corinne , Lamy Thierry , Copie-Bergman Christiane , Fabiani Bettina , Delarue Richard , Peyrade Frédéric , André Marc , Ketterer Nicolas , Leroy Karen , Salles Gilles , Molina Thierry J. , Tilly Hervé , Jardin Fabrice
Published: April 2023

Supplementary methods, supplementary figure & table legends, and supplementary tables 3, 4, 8 & 9. Table S3: Overview of the Lymphopanel used for NGS analysis. Table S4: Overview of pathway selection Table S8. Genes involved in the LPS score. Table S9. Expression levels of genes involved in response to LPS stimulation according to MYD88 L265P.
Supplemental Figures and Tables from Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
Authors: Afghahi Anosheh , Purington Natasha , Han Summer S. , Desai Manisha , Pierson Emma , Mathur Maya B. , Seto Tina , Thompson Caroline A. , Rigdon Joseph , Telli Melinda L. , Badve Sunil S. , Curtis Christina N. , West Robert B. , Horst Kathleen , Gomez Scarlett L. , Ford James M. , Sledge George W. , Kurian Allison W.
Published: April 2023

Supplemental Figure 1. Patient inclusion and exclusion criteria. TNBC: triple negative breast cancer; ALC: absolute lymphocyte count; nSES: neighborhood socioeconomic status. Supplemental Figure 2a and 2b. Association between minimum lymphocyte count (as percentage of total white blood cell count and absolute value) and stromal tumor infiltrating lymphocytes (sTILs), N=77. Figure 2a. sTILs were correlated with minimum % lymphocyte (p=0.02). Figure 2b. sTILs did not have a significant correlation with minimum absolute (abs) lymphocytes (p=0.36) Supplemental Figure 3. Comparison between Absolute Lymphocyte Count (ALC) and percent peripheral lymphocytes Supplemental Figure 4. Distribution of Absolute Lymphocyte Count (ALC) measures at baseline, defined as ALC value measured within the first three months of breast cancer diagnosis. Supplemental Figure 5. Distribution of minimum Absolute Lymphocyte Count (ALC) values at any time point Supplemental Figure 6. Distribution of overall minimum Absolute Lymphocyte Count (ALC) over time Supplemental Table 1. Multivariable analysis of predictors of lymphopenia (absolute lymphocyte count [ALC] <1K/ï�­L; n=747); statistically significant variables are in bold font. Supplemental Table 2. Multivariable analysis of the association between minimum absolute lymphocyte count (ALC) and breast cancer-specific mortality using complete case analysis (n=747) â€ Supplemental Table 3. Multivariable analysis of the association between minimum absolute lymphocyte count (ALC) and breast cancer-specific mortality using multiple imputation methods Supplemental Table 4. Multivariable analysis of the association between minimum ALC and OM with RT temporal consideration (n=747) Supplemental Table 5. Multivariable analysis of the association between minimum ALC and BCM with RT temporal consideration (n=747) Supplemental Table 6. Multivariable analysis of the association between minimum ALC and OM with neutropenia temporal consideration (n=747) Supplemental Table 7. Multivariable analysis of the association between minimum ALC and BCM with neutropenia temporal consideration (n=747) Supplemental Table 8. Multivariable analysis of the association between minimum percent lymphocyte count and overall mortality using complete case analysis (n=532). Supplemental Table 9. Multivariable analysis of the association between minimum percent lymphocyte count and breast-cancer specific mortality using complete case analysis (n=532)
Figures S1-S7, Tables S1-S10 from PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer
Authors: Lamprecht Sebastian , Kaller Markus , Schmidt Eva Marina , Blaj Cristina , Schiergens Tobias S. , Engel Jutta , Jung Andreas , Hermeking Heiko , Grünewald Thomas G.P. , Kirchner Thomas , Horst David
Published: April 2023

Figure S1. Specificity of PBX3 protein detection. Figure S2. Effects of WNT repression on PBX3 in colon cancer cells. Figure S3. Lack of transcriptional regulation of PBX3 expression by WNT. Figure S4. Effects of EMT induction with a conditional ZEB1 allele in LS174T and DLD-1 colon cancer cells. Figure S5. Effects of ZEB1 depletion on PBX3 expression. Figure S6. Effects of PBX3 depletion on VIM expression upon EMT induction by SNAIL. Figure S7. PBX3, ZEB1 and SNAIL mRNA expression and disease free survival in n=786 colon cancer cases. Table S1. Antibodies used. Table S2. qRT-PCR primers. Table S3. Differentially expressed transcription factors. Table S4. PBX3 in UICC II colorectal cancer. Table S5. Multivariate analysis of cancer specific survival in UICC stage II colorectal cancer. Table S6. Multivariate analysis of disease free survival in UICC stage II colorectal cancer. Table S7. PBX3 expression in colon cancers with and without distant metastasis. Table S8. Multivariate analysis for PBX3 mRNA expression. Table S9. Multivariate analysis for ZEB1 mRNA expression. Table S10. Multivariate analysis for SNAIL mRNA expression.
Table S2 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Case processing summary (upper tables) and overall comparisons (lower tables) for the tissue microarray (TMA) analysis performed on 145 primary, stage II-III, HER2+ breast cancer tissues. Statistics was performed using Log Rank (Mantel-Cox test).
Table S1 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Primer Sequences for RT-PCR
Supp Figure 3 from TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer
Authors: Murcia Oscar , Jover Rodrigo , Egoavil Cecilia , Perez-Carbonell Lucia , Juárez Miriam , Hernández-Illán Eva , Rojas Estefania , Alenda Cristina , Balaguer Francesc , Andreu Montserrat , Llor Xavier , Castells Antoni , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary Figure 3. Correlation between TFAP2E intron 3 methylation and IHC expression. When methylation was analysed as a continuous variable using linear regression analysis, we observed a trend towards negative correlation with IHC protein expression; however, this correlation was significant only when combining lack of and low TFAP2E expression (IHC scores 0 & 1) versus strong TFAP2E staining (IHC scores 2 & 3) (p= 0.015). Linear regression analysis comparing TFAP2E methylation and expression in CRC tissues (N=314) using IHC results by binary scoring system: positive/negative (A) staining scores 0 & 1 vs 2 & 3(B) and the staining intensity scale 0 to 3 (C). Correlation and performance measures between TFAP2E methylation and expression in CRC tissues using IHC and methylation qualitative results (staining scores 0 & 1 vs 2 & 3; (D).
Figure S5 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Lapatinib-induced Jagged-1 high expressing HCC1954 cells continue to cycle in S-phase.
Figure S3 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Lapatinib induces Jagged1 transcripts but decreases total protein expression.
Supplementary Table 1 from Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Authors: Lee Jung-Min , Peer Cody J. , Yu Minshu , Amable Lauren , Gordon Nicolas , Annunziata Christina M. , Houston Nicole , Goey Andrew K.L. , Sissung Tristan M. , Parker Bernard , Minasian Lori , Chiou Victoria L. , Murphy Robert F. , Widemann Brigitte C. , Figg William D. , Kohn Elise C.
Published: April 2023

Dose Levels
Supplementary Data from Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Authors: Lee Jung-Min , Peer Cody J. , Yu Minshu , Amable Lauren , Gordon Nicolas , Annunziata Christina M. , Houston Nicole , Goey Andrew K.L. , Sissung Tristan M. , Parker Bernard , Minasian Lori , Chiou Victoria L. , Murphy Robert F. , Widemann Brigitte C. , Figg William D. , Kohn Elise C.
Published: April 2023

Supplementary method 1. DNA platinum-adducts measurement
Figure S1 from Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Authors: Shah Deep , Wyatt Debra , Baker Andrew T. , Simms Patricia , Peiffer Daniel S. , Fernandez Michelle , Rakha Emad , Green Andrew , Filipovic Alexandra , Miele Lucio , Osipo Clodia
Published: April 2023

Differential growth effects of lapatinib on bulk HER2+ and HER2- breast cancer cell lines.
Table S2 from A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Authors: Gedeon Patrick C. , Schaller Teilo H. , Chitneni Satish K. , Choi Bryan D. , Kuan Chien-Tsun , Suryadevara Carter M. , Snyder David J. , Schmittling Robert J. , Szafranski Scott E. , Cui Xiuyu , Healy Patrick N. , Herndon James E. , McLendon Roger E. , Keir Stephen T. , Archer Gary E. , Reap Elizabeth A. , Sanchez-Perez Luis , Bigner Darell D. , Sampson John H.
Published: April 2023

Table S2 - Glioma cell lines and patient derived tumor samples used for study with the number of EGFRvIII receptors per cell, the number of EGFRwt receptors per cell and the proportion of cells expressing EGFRvIII in the given cell line or tumor sample.
Supplementary tables from t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
Authors: Lenz Gal , Hamilton Angelica , Geng Shuhui , Hong Teresa , Kalkum Markus , Momand Jamil , Kane Susan E. , Huss Janice M.
Published: April 2023

Table S1. Co-occurrence analysis of PPP1R1B and IGF-1R transcripts Table S2. Hazard ratios associated with PPP1R1B and IGF-1R expression Table S3. Multivariate analysis of PPP1R1B and IGF-1R with HER2 for OS
Supplemental Methods from t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
Authors: Lenz Gal , Hamilton Angelica , Geng Shuhui , Hong Teresa , Kalkum Markus , Momand Jamil , Kane Susan E. , Huss Janice M.
Published: April 2023

Expanded methods
Table S5 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Authors: Ye Mingxiang , Zhang Yong , Gao Hongjun , Xu Yan , Jing Pengyu , Wu Jianxiong , Zhang Xinxin , Xiong Jie , Dong Chenfang , Yao Libo , Zhang Jian
Published: April 2023

Expression of AhR protein in 57 lung adenocarcinoma cases and its association with metastasis.
Table S3 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Authors: Ye Mingxiang , Zhang Yong , Gao Hongjun , Xu Yan , Jing Pengyu , Wu Jianxiong , Zhang Xinxin , Xiong Jie , Dong Chenfang , Yao Libo , Zhang Jian
Published: April 2023

qPCR primer sequence (5'â†'3').
Table S1 from Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
Authors: Ye Mingxiang , Zhang Yong , Gao Hongjun , Xu Yan , Jing Pengyu , Wu Jianxiong , Zhang Xinxin , Xiong Jie , Dong Chenfang , Yao Libo , Zhang Jian
Published: April 2023

pLKO.1-shRNA sequence (5'â†'3').
Figure S4 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

VISTA expression in non-tumor lung and NSCLC
Figure S3 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Patterns of tumor VISTA expression